Heitor Ribeiro da Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Heitor Ribeiro da Silva has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- José Carlos Tavares Carvalho
Universidade Federal do Amapá, Macapa, Brazil, Brazil
9 shared publications - Aline Lopes Do Nascimento
Departamento de Ciencias Biológicas e da Saúde, Universidade Federal do Amapá, Macapa, Brazil, Brazil
5 shared publications - Arlindo César Matias Pereira
Faculty of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo, Ribeirão Preto 14040-020, SP, Brazil
5 shared publications - Helison de Oliveira Carvalho
Ciências Biológicas e da Saúde, Universidade Federal do Amapá, Macapa, Brazil, Brazil
4 shared publications - Gabriel da Costa Furtado
Federal University of Amapá, Brazil
3 shared publications - Priscila Faimann Sales
Graduate Program in Pharmaceutical Innovation, Department of Biological and Health Sciences, Universidade Federal do Amapá, Rodovia Josmar Chaves Pinto, Km 02, Macapá CEP 68903-419, AP, Brazil
3 shared publications
Latest Publications
- Open Access
- 9 June 2026
- Published by MDPI AG in Preprints.org
In Vitro and In Silico Studies: Evidence of the Phytoestrogenic and Antioxidant Properties of Ormona® for Menopausal Health
Menopause is associated with a progressive decline in estrogen levels, which contributes to increased oxidative stress, inflammatory processes, and metabolic and bone alterations that may favor the development of chronic conditions such as osteoporosis and cardiovascular diseases. Due to the potential risks associated with long-term hormone replacement therapy, the use of nutraceutical formulations containing phytoestrogens and antioxidant compounds has emerged as a potential alternative for the management of menopausal symptoms and associated metabolic alterations. In this context, the present study aimed to conduct the pharmacotechnical and phytochemical characterization of the nutraceutical formulation Ormona®, as well as to evaluate its antioxidant activity, cytotoxicity, anti-inflammatory potential, and molecular interactions with biological targets involved in estrogen signaling using integrated in silico and in vitro approaches. Pharmacotechnical analyses included weight variation, hardness, friability, and disintegration tests in order to evaluate the quality, uniformity, and stability of the formulation. Phytochemical screening and antioxidant activity were evaluated using the DPPH and ABTS radical-scavenging assays. In silico molecular docking studies were performed to investigate the interactions between the bioactive compounds present in the formulation and estrogen receptors and proteins involved in inflammatory pathways. In vitro assays were conducted to evaluate cytotoxicity in MRC-5 fibroblasts and anti-inflammatory activity by inhibiting nitric oxide production in macrophages. The formulation demonstrated satisfactory pharmacotechnical properties, relevant antioxidant activity, low cytotoxicity in fibroblast cells, potential anti-inflammatory activity, and favorable molecular interactions with estrogen receptors and inflammatory targets. These findings suggest that Ormona® may represent a promising nutraceutical formulation for menopausal health, acting through antioxidant, anti-inflammatory, and estrogen receptor-related mechanisms. However, further experimental and clinical studies are necessary to confirm its biological effects and therapeutic potential.
- 9 June 2026
- Published by MDPI AG in Preprints.org
Open AccessIn Vitro and In Silico Studies: Evidence of the Phytoestrogenic and Antioxidant Properties of Ormona® for Menopausal Health
Menopause is associated with a progressive decline in estrogen levels, which contributes to increased oxidative stress, inflammatory processes, and metabolic and bone alterations that may favor the development of chronic conditions such as osteoporosis and cardiovascular diseases. Due to the potential risks associated with long-term hormone replacement therapy, the use of nutraceutical formulations containing phytoestrogens and antioxidant compounds has emerged as a potential alternative for the management of menopausal symptoms and associated metabolic alterations. In this context, the present study aimed to conduct the pharmacotechnical and phytochemical characterization of the nutraceutical formulation Ormona®, as well as to evaluate its antioxidant activity, cytotoxicity, anti-inflammatory potential, and molecular interactions with biological targets involved in estrogen signaling using integrated in silico and in vitro approaches. Pharmacotechnical analyses included weight variation, hardness, friability, and disintegration tests in order to evaluate the quality, uniformity, and stability of the formulation. Phytochemical screening and antioxidant activity were evaluated using the DPPH and ABTS radical-scavenging assays. In silico molecular docking studies were performed to investigate the interactions between the bioactive compounds present in the formulation and estrogen receptors and proteins involved in inflammatory pathways. In vitro assays were conducted to evaluate cytotoxicity in MRC-5 fibroblasts and anti-inflammatory activity by inhibiting nitric oxide production in macrophages. The formulation demonstrated satisfactory pharmacotechnical properties, relevant antioxidant activity, low cytotoxicity in fibroblast cells, potential anti-inflammatory activity, and favorable molecular interactions with estrogen receptors and inflammatory targets. These findings suggest that Ormona® may represent a promising nutraceutical formulation for menopausal health, acting through antioxidant, anti-inflammatory, and estrogen receptor-related mechanisms. However, further experimental and clinical studies are necessary to confirm its biological effects and therapeutic potential.
- Open Access
- 1 April 2025
- Published by MDPI AG in Preprints.org
Acute Toxicity Study and Anti-Inflammatory Effect of Injectable Nanodispersion of Bixa orellana L. (Chronic In®) in Danio rerio (Zebrafish)
Medicinal plants hold great potential for the development of drugs to treat inflammatory diseases. Bixa orellana L, popularly known as “annatto” or “urucum”, stands out among various species. The Zebrafish (Danio rerio) is a small tropical freshwater fish which, due to its experimental attributes, has been highlighted as an experimental model in pharmacological and toxicological tests of new drugs. This study aims to evaluate the acute toxicological effects and anti-inflammatory activity of the injectable nanodispersion of Bixa orellana (NBO, Chronic In®) in zebrafish. The stability of the NBO was assessed with an average particle size ranging from 53.15 ± 0.64 nm to 59.90 ± 3.63 nm. The acute toxicity study used intraperitoneal doses of NBO ranging from 250 to 1500 mg/kg. The results showed significant toxic effects at doses of 750, 1000, and 1500 mg/kg with histopathological changes in the liver, kidneys, and intestine. The 50% lethal dose (LD50) calculation corresponded to 830.6 mg/kg. In silico tests suggest that the detected toxicity mechanism may be related to the inhibition of the cardiac potassium channel (hERG II) and/or the inhibition of the TNF tumor necrosis factor receptor-associated protein 1 (TRAP1). In the anti-inflammatory evaluation of NBO in a model of intraperitoneal edema induced by carrageenan in Zebrafish, a significant anti-inflammatory effect was observed at doses of 20 and 40 mg/kg (i.p), without significant histopathological alterations in the organs evaluated. In summary, NBO has an anti-inflammatory effect at low doses and demonstrated that doses of NBO ranging from 500 to 1500 mg/kg applied intraperitoneally were unsafe and showed toxic effects and lethality as the dose increased.
- 1 April 2025
- Published by MDPI AG in Preprints.org
Open AccessAcute Toxicity Study and Anti-Inflammatory Effect of Injectable Nanodispersion of Bixa orellana L. (Chronic In®) in Danio rerio (Zebrafish)
Medicinal plants hold great potential for the development of drugs to treat inflammatory diseases. Bixa orellana L, popularly known as “annatto” or “urucum”, stands out among various species. The Zebrafish (Danio rerio) is a small tropical freshwater fish which, due to its experimental attributes, has been highlighted as an experimental model in pharmacological and toxicological tests of new drugs. This study aims to evaluate the acute toxicological effects and anti-inflammatory activity of the injectable nanodispersion of Bixa orellana (NBO, Chronic In®) in zebrafish. The stability of the NBO was assessed with an average particle size ranging from 53.15 ± 0.64 nm to 59.90 ± 3.63 nm. The acute toxicity study used intraperitoneal doses of NBO ranging from 250 to 1500 mg/kg. The results showed significant toxic effects at doses of 750, 1000, and 1500 mg/kg with histopathological changes in the liver, kidneys, and intestine. The 50% lethal dose (LD50) calculation corresponded to 830.6 mg/kg. In silico tests suggest that the detected toxicity mechanism may be related to the inhibition of the cardiac potassium channel (hERG II) and/or the inhibition of the TNF tumor necrosis factor receptor-associated protein 1 (TRAP1). In the anti-inflammatory evaluation of NBO in a model of intraperitoneal edema induced by carrageenan in Zebrafish, a significant anti-inflammatory effect was observed at doses of 20 and 40 mg/kg (i.p), without significant histopathological alterations in the organs evaluated. In summary, NBO has an anti-inflammatory effect at low doses and demonstrated that doses of NBO ranging from 500 to 1500 mg/kg applied intraperitoneally were unsafe and showed toxic effects and lethality as the dose increased.
- Open Access
- 22 March 2024
- Published by MDPI AG in Nutraceuticals
- Vol. 4 (2) , 147-164
Osteoprotective Effect of the Phytonutraceutical Ormona® on Ovariectomy-Induced Osteoporosis in Wistar Rats
The phytonutraceutical Ormona® is a product composed of purified oil of Bixa orellana Linné, dry extract of Myrciaria dubia McVaugh, dry extract of Trifolium pratense L., and dry extract of Euterpe oleracea Mart. obtained using Evolve® technology. This study evaluated the effects of Ormona® on Wistar rats affected by ovariectomy-induced osteoporosis. Pre-treatment was conducted for 15 days before surgery and continued for a further 45 days after the surgical procedure. The experimental design consisted of five groups (n = 5): OVW: treated with distilled water (1 mL/kg, p.o); ADS: alendronate sodium (4 mg/kg p.o); EST: conjugated estrogen (2 µg/kg, p.o); ORM: Ormona® (20 mg/kg, p.o); ORM + EST: Ormona® (20 mg/kg, p.o) + conjugated estrogen (2 µg/kg, p.o). Biochemical and hormonal parameters of bone histopathology and trabecular and femoral diaphysis size were evaluated through scanning electron microscopy (SEM) and bone calcium quantification by atomic absorption spectrophotometry. The results show that ovariectomy caused bone alterations such as loss of femoral microarchitecture, decreased bone homeostasis parameters, and changes in the lipid profile. Estrogen supplementation reduced parameters such as cholesterol, LDL, and Ca2+ concentration. However, Ormona® showed higher serum estradiol levels (p < 0.01), effects on the lipid profile, including parameters that estrogen replacement and alendronate sodium did not affect, with an increase in HDL, and positive modulation of bone metabolism, increasing osteocytes and the presence of osteoblasts. Ormona®, therefore, produced better results than the groups treated with estrogen and alendronate sodium.
- 22 March 2024
- Published by MDPI AG in Nutraceuticals
- Vol. 4 (2) , 147-164
Open AccessOsteoprotective Effect of the Phytonutraceutical Ormona® on Ovariectomy-Induced Osteoporosis in Wistar Rats
The phytonutraceutical Ormona® is a product composed of purified oil of Bixa orellana Linné, dry extract of Myrciaria dubia McVaugh, dry extract of Trifolium pratense L., and dry extract of Euterpe oleracea Mart. obtained using Evolve® technology. This study evaluated the effects of Ormona® on Wistar rats affected by ovariectomy-induced osteoporosis. Pre-treatment was conducted for 15 days before surgery and continued for a further 45 days after the surgical procedure. The experimental design consisted of five groups (n = 5): OVW: treated with distilled water (1 mL/kg, p.o); ADS: alendronate sodium (4 mg/kg p.o); EST: conjugated estrogen (2 µg/kg, p.o); ORM: Ormona® (20 mg/kg, p.o); ORM + EST: Ormona® (20 mg/kg, p.o) + conjugated estrogen (2 µg/kg, p.o). Biochemical and hormonal parameters of bone histopathology and trabecular and femoral diaphysis size were evaluated through scanning electron microscopy (SEM) and bone calcium quantification by atomic absorption spectrophotometry. The results show that ovariectomy caused bone alterations such as loss of femoral microarchitecture, decreased bone homeostasis parameters, and changes in the lipid profile. Estrogen supplementation reduced parameters such as cholesterol, LDL, and Ca2+ concentration. However, Ormona® showed higher serum estradiol levels (p < 0.01), effects on the lipid profile, including parameters that estrogen replacement and alendronate sodium did not affect, with an increase in HDL, and positive modulation of bone metabolism, increasing osteocytes and the presence of osteoblasts. Ormona®, therefore, produced better results than the groups treated with estrogen and alendronate sodium.
- Open Access
- 28 November 2023
- Published by MDPI AG in Preprints.org
Osteoprotective Effect of the Phytonutraceutical Ormona® on Post-Menopausal Osteoporosis in Wistar Rats
The phytonutraceutical Ormona® is a product composed of: purified oil of Bixa orellana Linné; dry extract of Myrciaria dubia McVaugh; dry extract of Trifolium pratense L. and dry extract of Euterpe oleracea Mart. obtained using Evolve® technology. This study evaluated the effects of Ormona® on Wistar rats affected by ovariectomy-induced osteoporosis. Pre-treatment was conducted for 15 days before surgery and continued for a further 45 days after the surgical procedure. The experimental design consisted of 5 groups (n=5): OVW: treated with distilled water (1 mL/ kg, p.o); ADS: alendronate sodium (4 mg/ kg p.o); EST: conjugated estrogen (2 ug/ kg, p.o); ORM: Ormona® (20 mg/kg, p.o); ORM + EST: Ormona® (20 mg/kg + conjugated estrogen 2 ug/ kg, p.o. Biochemical and hormonal parameters, along with bone histopathology and trabecular and femoral diaphysis size, were evaluated through Scanning Electron Microscopy (SEM) and bone calcium quantification by atomic absorption spectrophotometry. The results show that ovariectomy caused bone alterations such as loss of femoral microarchitecture, decreased bone homeostasis parameters, and changes in the lipid profile. Estrogen supplementation reduced parameters such as cholesterol, LDL, and Ca2+ concentration. However, Ormona® showed higher serum estradiol levels (p< 0.01), effects on the lipid profile, including parameters that estrogen replacement and alendronate sodium did not affect, with an increase in HDL, and positive modulation of bone metabolism, increasing osteocytes and the presence of osteoblasts. Ormona®, therefore, produced better results than the groups treated with estrogen and alendronate sodium.
- 28 November 2023
- Published by MDPI AG in Preprints.org
Open AccessOsteoprotective Effect of the Phytonutraceutical Ormona® on Post-Menopausal Osteoporosis in Wistar Rats
The phytonutraceutical Ormona® is a product composed of: purified oil of Bixa orellana Linné; dry extract of Myrciaria dubia McVaugh; dry extract of Trifolium pratense L. and dry extract of Euterpe oleracea Mart. obtained using Evolve® technology. This study evaluated the effects of Ormona® on Wistar rats affected by ovariectomy-induced osteoporosis. Pre-treatment was conducted for 15 days before surgery and continued for a further 45 days after the surgical procedure. The experimental design consisted of 5 groups (n=5): OVW: treated with distilled water (1 mL/ kg, p.o); ADS: alendronate sodium (4 mg/ kg p.o); EST: conjugated estrogen (2 ug/ kg, p.o); ORM: Ormona® (20 mg/kg, p.o); ORM + EST: Ormona® (20 mg/kg + conjugated estrogen 2 ug/ kg, p.o. Biochemical and hormonal parameters, along with bone histopathology and trabecular and femoral diaphysis size, were evaluated through Scanning Electron Microscopy (SEM) and bone calcium quantification by atomic absorption spectrophotometry. The results show that ovariectomy caused bone alterations such as loss of femoral microarchitecture, decreased bone homeostasis parameters, and changes in the lipid profile. Estrogen supplementation reduced parameters such as cholesterol, LDL, and Ca2+ concentration. However, Ormona® showed higher serum estradiol levels (p< 0.01), effects on the lipid profile, including parameters that estrogen replacement and alendronate sodium did not affect, with an increase in HDL, and positive modulation of bone metabolism, increasing osteocytes and the presence of osteoblasts. Ormona®, therefore, produced better results than the groups treated with estrogen and alendronate sodium.
- Open Access
- 19 November 2022
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (11) , 1434
Acute and Reproductive Toxicity Evaluation of Ormona® SI and Ormona® RC—Two New Nutraceuticals with Geranylgeraniol, Tocotrienols, Anthocyanins, and Isoflavones—In Adult Zebrafish
The zebrafish is a popular organism to test the toxicity of compounds. Here, we evaluate the acute and reproductive toxicity of Ormona SI® (OSI) and RC® (ORC), two herbal products developed for menopausal women with tocotrienols, geranylgeraniol, isoflavones, and anthocyanins. The acute toxicity was evaluated by behavioral alterations, lethality, and tissue changes (intestine, liver, kidney) after oral treatment with high product doses (500, 1000, and 2000 mg/kg). The reproductive toxicity was evaluated after 21 days of oral treatment with OSI and ORC at 200 mg/kg. Our results show that the LD50 could not be assessed due to the low mortality rate even with the highest dose; the behavioral alterations were not different from those of the group treated only with the vehicle (2% DMSO). The tissue changes were minor in OSI and more severe in ORC at the highest (2000 mg/kg) dose, while no tissue abnormality was observed at 500 mg/kg. In the reproductive assessment, continuous treatment could decrease the maturation of the reproductive cells, which also significantly decreases the egg spawning. This effect was attributed to the estrogenic activity of the isoflavones. In conclusion, the acute toxicity analysis shows that the products did not elicit lethal or sublethal effects observed in the model when used up to 500 mg/kg. Regarding the reproductive toxicity, decreased fertility was observed, which was expected due to the presence of isoflavones (phytoestrogens). Considering that the product is intended for menopausal and postmenopausal women, the presence of isoflavones is beneficial. Further studies should be performed to corroborate these results in mammals.
- 19 November 2022
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (11) , 1434
Open AccessAcute and Reproductive Toxicity Evaluation of Ormona® SI and Ormona® RC—Two New Nutraceuticals with Geranylgeraniol, Tocotrienols, Anthocyanins, and Isoflavones—In Adult Zebrafish
The zebrafish is a popular organism to test the toxicity of compounds. Here, we evaluate the acute and reproductive toxicity of Ormona SI® (OSI) and RC® (ORC), two herbal products developed for menopausal women with tocotrienols, geranylgeraniol, isoflavones, and anthocyanins. The acute toxicity was evaluated by behavioral alterations, lethality, and tissue changes (intestine, liver, kidney) after oral treatment with high product doses (500, 1000, and 2000 mg/kg). The reproductive toxicity was evaluated after 21 days of oral treatment with OSI and ORC at 200 mg/kg. Our results show that the LD50 could not be assessed due to the low mortality rate even with the highest dose; the behavioral alterations were not different from those of the group treated only with the vehicle (2% DMSO). The tissue changes were minor in OSI and more severe in ORC at the highest (2000 mg/kg) dose, while no tissue abnormality was observed at 500 mg/kg. In the reproductive assessment, continuous treatment could decrease the maturation of the reproductive cells, which also significantly decreases the egg spawning. This effect was attributed to the estrogenic activity of the isoflavones. In conclusion, the acute toxicity analysis shows that the products did not elicit lethal or sublethal effects observed in the model when used up to 500 mg/kg. Regarding the reproductive toxicity, decreased fertility was observed, which was expected due to the presence of isoflavones (phytoestrogens). Considering that the product is intended for menopausal and postmenopausal women, the presence of isoflavones is beneficial. Further studies should be performed to corroborate these results in mammals.
- Open Access
- 26 October 2022
- Published by MDPI AG in Nutraceuticals
- Vol. 2 (4) , 311-322
Ormona® SI and Ormona® RC—New Nutraceuticals with Geranylgeraniol, Tocotrienols, Anthocyanins, and Isoflavones—Decrease High-Fat Diet-Induced Dyslipidemia in Wistar Rats
Dyslipidemia is a metabolic condition linked to increased morbidity. This study aimed to evaluate the effect of two new nutraceuticals derived from annatto (Bixa orellana), açaí (Euterpe oleracea), and soybean germ or red clover isoflavones (Trifolium pratense) against high-fat-induced dyslipidemia in female Wistar rats. The formulations were assessed through GC-MS and HPLC-UV/Vis. Next, female Wistar rats received daily administrations of coconut oil and were treated with Ormona® SI (OSI), Ormona® RC (ORC), soybean germ (SG), simvastatin (simv.), simvastatin + Ormona® SI (simv. + OSI), or only distilled water (control). Biochemical tests were performed using the animals’ blood, and their arteries were screened for atheroma formation. The results show abnormal TC, TG, LDL, and HDL levels caused by the high-fat diet, increased glucose levels, hepatotoxicity, nephrotoxicity, and atherogenesis. The nutraceuticals significantly ameliorated all conditions, with results that are similar to the group treated with simvastatin. Notably, the groups treated with either Ormona® or simvastatin + Ormona® had better liver protection than those treated only with SG or simvastatin; additionally, the nutraceuticals could prevent atherogenesis, unlike SG. The results indicate a high efficacy of the nutraceuticals in preventing dyslipidemia and its complications.
- 26 October 2022
- Published by MDPI AG in Nutraceuticals
- Vol. 2 (4) , 311-322
Open AccessOrmona® SI and Ormona® RC—New Nutraceuticals with Geranylgeraniol, Tocotrienols, Anthocyanins, and Isoflavones—Decrease High-Fat Diet-Induced Dyslipidemia in Wistar Rats
Dyslipidemia is a metabolic condition linked to increased morbidity. This study aimed to evaluate the effect of two new nutraceuticals derived from annatto (Bixa orellana), açaí (Euterpe oleracea), and soybean germ or red clover isoflavones (Trifolium pratense) against high-fat-induced dyslipidemia in female Wistar rats. The formulations were assessed through GC-MS and HPLC-UV/Vis. Next, female Wistar rats received daily administrations of coconut oil and were treated with Ormona® SI (OSI), Ormona® RC (ORC), soybean germ (SG), simvastatin (simv.), simvastatin + Ormona® SI (simv. + OSI), or only distilled water (control). Biochemical tests were performed using the animals’ blood, and their arteries were screened for atheroma formation. The results show abnormal TC, TG, LDL, and HDL levels caused by the high-fat diet, increased glucose levels, hepatotoxicity, nephrotoxicity, and atherogenesis. The nutraceuticals significantly ameliorated all conditions, with results that are similar to the group treated with simvastatin. Notably, the groups treated with either Ormona® or simvastatin + Ormona® had better liver protection than those treated only with SG or simvastatin; additionally, the nutraceuticals could prevent atherogenesis, unlike SG. The results indicate a high efficacy of the nutraceuticals in preventing dyslipidemia and its complications.
- Open Access
Potential of the Compounds from Bixa orellana Purified Annatto Oil and Its Granules (Chronic®) against Dyslipidemia and Inflammatory Diseases: In Silico Studies with Geranylgeraniol and Tocotrienols
Some significant compounds present in annatto are geranylgeraniol and tocotrienols. These compounds have beneficial effects against hyperlipidemia and chronic diseases, where oxidative stress and inflammation are present, but the exact mechanism of action of such activities is still a subject of research. This study aimed to evaluate possible mechanisms of action that could be underlying the activities of these molecules. For this, in silico approaches such as ligand topology (PASS and SEA servers) and molecular docking with the software GOLD were used. Additionally, we screened some pharmacokinetic and toxicological parameters using the servers PreADMET, SwissADME, and ProTox-II. The results corroborate the antidyslipidemia and anti-inflammatory activities of geranylgeraniol and tocotrienols. Notably, some new mechanisms of action were predicted to be potentially underlying the activities of these compounds, including inhibition of squalene monooxygenase, lanosterol synthase, and phospholipase A2. These results give new insight into new mechanisms of action involved in these molecules from annatto and Chronic®.
Open AccessPotential of the Compounds from Bixa orellana Purified Annatto Oil and Its Granules (Chronic®) against Dyslipidemia and Inflammatory Diseases: In Silico Studies with Geranylgeraniol and Tocotrienols
Some significant compounds present in annatto are geranylgeraniol and tocotrienols. These compounds have beneficial effects against hyperlipidemia and chronic diseases, where oxidative stress and inflammation are present, but the exact mechanism of action of such activities is still a subject of research. This study aimed to evaluate possible mechanisms of action that could be underlying the activities of these molecules. For this, in silico approaches such as ligand topology (PASS and SEA servers) and molecular docking with the software GOLD were used. Additionally, we screened some pharmacokinetic and toxicological parameters using the servers PreADMET, SwissADME, and ProTox-II. The results corroborate the antidyslipidemia and anti-inflammatory activities of geranylgeraniol and tocotrienols. Notably, some new mechanisms of action were predicted to be potentially underlying the activities of these compounds, including inhibition of squalene monooxygenase, lanosterol synthase, and phospholipase A2. These results give new insight into new mechanisms of action involved in these molecules from annatto and Chronic®.
- Open Access
Co-Treatment of Purified Annatto Oil (Bixa orellana L.) and Its Granules (Chronic®) Improves the Blood Lipid Profile and Bone Protective Effects of Testosterone in the Orchiectomy-Induced Osteoporosis in Wistar Rats
This study aimed to evaluate and compare the effects of co-treatment with purified annatto oil (PAO) or its granules (GRA, Chronic®) with that of testosterone on the orchiectomy-induced osteoporosis in Wistar rats. After surgery, rats were treated from day 7 until day 45 with testosterone only (TES, 7 mg/kg, IM) or TES + PAO or GRA (200 mg/kg, p.o.). The following parameters were evaluated: food/water intake, weight, HDL, LDL, glucose, triglycerides (TG), total cholesterol (TC), alkaline phosphatase levels, blood phosphorus and calcium contents, femur weight, structure (through scanning electron microscopy), and calcium content (through atomic absorption spectrophotometry). Our results show that orchiectomy could significantly change the blood lipid profile and decrease bone integrity parameters. Testosterone reposition alone could improve some endpoints, including LDL, TC, bone weight, and bone calcium concentration. However, other parameters were not significantly improved. Co-treatment with PAO or GRA improved the blood lipid profile and bone integrity more significantly and improved some endpoints not affected by testosterone reposition alone (such as TG levels and trabeculae sizes). The results suggest that co-treatment with annatto products improved the blood lipid profile and the anti-osteoporosis effects of testosterone. Overall, GRA had better results than PAO.
Open AccessCo-Treatment of Purified Annatto Oil (Bixa orellana L.) and Its Granules (Chronic®) Improves the Blood Lipid Profile and Bone Protective Effects of Testosterone in the Orchiectomy-Induced Osteoporosis in Wistar Rats
This study aimed to evaluate and compare the effects of co-treatment with purified annatto oil (PAO) or its granules (GRA, Chronic®) with that of testosterone on the orchiectomy-induced osteoporosis in Wistar rats. After surgery, rats were treated from day 7 until day 45 with testosterone only (TES, 7 mg/kg, IM) or TES + PAO or GRA (200 mg/kg, p.o.). The following parameters were evaluated: food/water intake, weight, HDL, LDL, glucose, triglycerides (TG), total cholesterol (TC), alkaline phosphatase levels, blood phosphorus and calcium contents, femur weight, structure (through scanning electron microscopy), and calcium content (through atomic absorption spectrophotometry). Our results show that orchiectomy could significantly change the blood lipid profile and decrease bone integrity parameters. Testosterone reposition alone could improve some endpoints, including LDL, TC, bone weight, and bone calcium concentration. However, other parameters were not significantly improved. Co-treatment with PAO or GRA improved the blood lipid profile and bone integrity more significantly and improved some endpoints not affected by testosterone reposition alone (such as TG levels and trabeculae sizes). The results suggest that co-treatment with annatto products improved the blood lipid profile and the anti-osteoporosis effects of testosterone. Overall, GRA had better results than PAO.
- Open Access
- 11 July 2019
- Published by MDPI AG in Pharmaceuticals
- Vol. 12 (3) , 106
Anxiolytic and Antidepressant Effects of the Hydroethanolic Extract from the Leaves of Aloysia polystachya (Griseb.) Moldenke: A Study on Zebrafish (Danio rerio)
Medicinal plants such as Aloysia polystachya are often used in the treatment of psychiatric diseases, including anxiety- and depression-related humor disturbances. In folk medicine, A. polystachya is used to treat digestive and respiratory tract disturbances, as a sedative and antidepressant agent, and as a tonic for the nerves. This study aimed to evaluate the antidepressant and anxiolytic effect from the hydroethanolic extract from the leaves of Aloysia polystachya (HELAp) in zebrafish. The extract was analyzed through ultra-performance liquid chromatography-mass spectroscopy (UPLC-MS) and the main compound detected was acteoside. HELAp was administered orally (10 mg/kg) and through immersion (mg/L). The anxiolytic activity was evaluated through the scototaxis (light–dark) test using caffeine as an anxiogenic agent and buspirone as a positive control. The parameters assessed were: period spent in the white compartment (s), latency (s), alternations (n), erratic swims (n), period of freezing (s), thigmotaxis (s), and risk evaluation (n). The antidepressant effect was evaluated through the novel tank diving test using 1% ethanol, unpredictable chronic stress, and social isolation as depressors; fluoxetine was used as a positive control. The parameters assessed were: period spent at the top of the tank, latency, quadrants crossed, erratic swim, period of freezing, and distance of swam. The main chemical compound of HELAp was acteoside. The administration of the extract on zebrafish managed to revert the anxiogenic effect of caffeine without impairing their locomotion. Additionally, the treatment exerted antidepressant activity similarly to fluoxetine. Overall, the results suggest a significant anxiolytic and antidepressant activity to the extract, which is probably due to the presence of the major compound, acteoside.
- 11 July 2019
- Published by MDPI AG in Pharmaceuticals
- Vol. 12 (3) , 106
Open AccessAnxiolytic and Antidepressant Effects of the Hydroethanolic Extract from the Leaves of Aloysia polystachya (Griseb.) Moldenke: A Study on Zebrafish (Danio rerio)
Medicinal plants such as Aloysia polystachya are often used in the treatment of psychiatric diseases, including anxiety- and depression-related humor disturbances. In folk medicine, A. polystachya is used to treat digestive and respiratory tract disturbances, as a sedative and antidepressant agent, and as a tonic for the nerves. This study aimed to evaluate the antidepressant and anxiolytic effect from the hydroethanolic extract from the leaves of Aloysia polystachya (HELAp) in zebrafish. The extract was analyzed through ultra-performance liquid chromatography-mass spectroscopy (UPLC-MS) and the main compound detected was acteoside. HELAp was administered orally (10 mg/kg) and through immersion (mg/L). The anxiolytic activity was evaluated through the scototaxis (light–dark) test using caffeine as an anxiogenic agent and buspirone as a positive control. The parameters assessed were: period spent in the white compartment (s), latency (s), alternations (n), erratic swims (n), period of freezing (s), thigmotaxis (s), and risk evaluation (n). The antidepressant effect was evaluated through the novel tank diving test using 1% ethanol, unpredictable chronic stress, and social isolation as depressors; fluoxetine was used as a positive control. The parameters assessed were: period spent at the top of the tank, latency, quadrants crossed, erratic swim, period of freezing, and distance of swam. The main chemical compound of HELAp was acteoside. The administration of the extract on zebrafish managed to revert the anxiogenic effect of caffeine without impairing their locomotion. Additionally, the treatment exerted antidepressant activity similarly to fluoxetine. Overall, the results suggest a significant anxiolytic and antidepressant activity to the extract, which is probably due to the presence of the major compound, acteoside.